This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
DENTSPLY (XRAY) Earnings and Revenues Miss Estimates in Q2
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) reported lukewarm second-quarter results owing to inventory reduction related to a change in the distribution strategy in North America and lower equipment sales to end users.
C.R. Bard Shareholders Approve Merger With Becton, Dickinson
by Zacks Equity Research
C. R. Bard, Inc. (BCR) announced that the majority of its shareholders have approved its merger with Becton, Dickinson and Company (BDX).
Luminex (LMNX) Beats Earnings & Revenue Estimates in Q2
by Zacks Equity Research
Luminex's (LMNX) assay business will be its key driver over the long term. The FDA go-ahead for Luminex ARIES Bordetella and ARIES C. Difficile assay were the key highlights of the second quarter.
Evolent Health (EVH) Posts Q2 Loss as Expected, Revenues Top
by Zacks Equity Research
Evolent Health's (EVH) strong rise in the number of members on its platform was the key highlight of the second quarter.
Envision Healthcare (EVHC) Q2 Earnings Beat, Revenues Miss
by Zacks Equity Research
Envision Healthcare's (EVHC) second-quarter results were positively impacted by strong Physician Services segment.
4 Medical Product Stocks Likely to Top Q2 Earnings Estimates
by Zacks Equity Research
There are some powerful long-term tailwinds in the medical space.
Surmodics (SRDX) Beats Earnings & Revenue Estimates in Q3
by Zacks Equity Research
Surmodics (SRDX) received IDE approval from the FDA for its TRANSCEND SurVeil DCB pivotal study in the third quarter. An upbeat guidance raises investor confidence.
PerkinElmer (PKI) Meets Q2 Earnings, Raises '17 Guidance
by Zacks Equity Research
PerkinElmer (PKI) posts tepid numbers in second quarter with in-line earnings and revenues missing the mark.
Can Myriad Genetics (MYGN) Spring a Surprise in Q4 Earnings?
by Zacks Equity Research
Myriad Genetics (MYGN) is well poised to deliver favorable results in Q4 riding on a diversified portfolio with products like Vectra DA test.
Becton, Dickinson (BDX) Beats on Q3 Earnings, Guidance Solid
by Zacks Equity Research
Becton, Dickinson and Company's (BDX) solid adjusted earnings guidance is likely to boost investor confidence. Solid revenue performance in the Life Sciences segment is a key third-quarter highlight.
Fresenius Medical (FMS) Q2 Earnings Miss, FY17 View Intact
by Zacks Equity Research
Despite margin contraction in the Dialysis and Care Coordination segments, Fresenius Medical Care (FMS) posted a strong second quarter on solid growth in Asia Pacific and Latin America.
Can CVS Health (CVS) Pull a Surprise this Earnings Season?
by Zacks Equity Research
CVS Health (CVS) is poised to gain on strong Pharmacy Services numbers that benefited from the upside in Specialty Pharmacy in Q2.
MedTech Stocks to Top Q2 Estimates
by Zacks Equity Research
Most of the MedTech majors are lined up to report their earnings results over the next week.
What's in the Offing for Hologic (HOLX) in Q3 Earnings?
by Zacks Equity Research
Hologic's (HOLX) gain through product launch and Cynosure integration may get hampered by a dull Cytology performance.
What's in the Cards for DaVita (DVA) this Earnings Season?
by Zacks Equity Research
Despite a stable Kidney Care business, escalating expenses is likely to mar DaVita's (DVA) performance in the second quarter.
Boston Scientific (BSX) Q2 Earnings: What Awaits the Stock?
by Zacks Equity Research
Lower TAVR sales due to recall of Lotus valves within the European and other key markets is likely to mar Boston Scientific's (BSX) top-line performance in Q2.
LabCorp (LH) Q2 Earnings: Is Disappointment in the Cards?
by Zacks Equity Research
With the Covance Drug Diagnostic arm's revenue and margins projected to decline further, LabCorp???s business in Q2 might face disruption.
What's in Store for athenahealth (ATHN) in Q2 Earnings?
by Zacks Equity Research
athenahealth Inc. (ATHN) is set to report second-quarter 2017 results on Jul 20.
Will Intuitive Surgical (ISRG) Surprise in Q2 Earnings?
by Zacks Equity Research
Intuitive Surgical Inc. (ISRG) is scheduled to report second-quarter 2017 results after the closing bell on Jul 20.
Will Thermo Fisher's (TMO) Q2 Earnings Surpass Expectations?
by Zacks Equity Research
Strong focus on product launch and emerging market expansion should drive Thermo Fisher (TMO) toward an earnings beat in Q2.
Can Abbott Laboratories (ABT) Pull a Surprise in Q2 Earnings?
by Zacks Equity Research
Abbott Laboratories (ABT) is scheduled to report second-quarter 2017 results before the opening bell on Jul 20.
Luminex (LMNX) Posts Loss in Q4, Revenues Miss Estimates
by Zacks Equity Research
Luminex Corporation (LMNX) reported loss of 8 cents per share in the fourth quarter of 2016, comparing unfavorably with the Zacks Consensus Estimate of adjusted earnings of 4 cents per share.
SurModics (SRDX) Beats Earnings & Revenue Estimates in Q1
by Zacks Equity Research
Surmodics, Inc. (SRDX) reported earnings of 19 cents per share in the first-quarter of fiscal 2017 surpassing the Zacks Consensus Estimate of 9 cents.
Pacific Biosciences (PACB) Q4 Loss Narrower than Estimated
by Zacks Equity Research
Pacific Biosciences of California Inc. (PACB), a pioneer in the field of single molecule long resequencing, reported loss of 21 cents per share in the fourth quarter of 2016, 2 cents narrower than the Zacks Consensus Estimate.
Abiomed (ABMD) Beats Earnings & Revenue Estimates in Q3
by Zacks Equity Research
Abiomed Inc. (ABMD) reported third-quarter fiscal 2017 earnings of 34 cents per share, which surpassed the Zacks Consensus Estimate by 5 cents and surged 47.8% from the year-ago quarter.